4D Pharma Is Latest Biotech Casualty After Creditor Calls Time

Third NASDAQ-Listed Biotech To Cease Trading In 2022

 
• By Andrew McConaghie
  
NASDAQ down
4D Pharma's demise is a symptom of the deep and prolonged bear market in early stage listed biotech sector. • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

More from Scrip